Samsung Biologics holds 11th Annual General Meeting of Shareholders

INCHEON, South Korea, March 28, 2022 /PRNewswire/ — Samsung Biologics (KRX: 207940.KS), the world’s main contract development and manufacturing business (CDMO), hosted its 11^th Yearly Normal Meeting of Shareholders (AGM) nowadays. Five issues have been presented and authorized unanimously at this year’s assembly, which involved the approval of monetary assertion, appointment of administrators, appointment of director as audit committee member, appointment of audit committee member, and approval of the remuneration restrict for the directors.

“As part of our eyesight, we are now venturing into the a few core pillars of our multidimensional expansion system, encompassing expanded producing potential, ongoing enhancements in business portfolio, and bigger global footprint,” reported John Rim, CEO of Samsung Biologics in an address to the shareholders. “As a leading CDMO service provider, we will go on to reveal our great business enterprise operations during our worth chains to in the end contribute to conserving the life of people and create a better future for all.”

Exact as past 12 months, Samsung Biologics carried out an electronic voting process, and the conference was made offered for digital participation via a live broadcast. Owing to the ongoing COVID-19 pandemic, the company took precautionary steps all through the assembly to make sure the wellbeing and safety of all attendees.

Samsung Biologics’ Plant 4 is now beneath stable building to get started operations by the finish of this calendar year, and the firm is steadily securing pre-income with shoppers. On the total completion of Plant 4 in 2023, the firm is predicted to keep the world’s major biomanufacturing ability. The corporation is further more seeking into securing supplemental websites in Songdo for its 2nd bio campus, and also overseas in many destinations to develop its organization in closer proximity to its world clients.

For additional information of the 2022 AGM, please see the reference product readily available under the subsequent website link.

Story carries on

About Samsung Biologics Co., Ltd.

Samsung Biologics (KRX: 207940.KS) is a entirely integrated CDMO giving state-of-the-art deal improvement, producing, and laboratory testing companies. With verified regulatory approvals, the premier capability, and the swiftest throughput, Samsung Biologics is an award-profitable companion of selection and is uniquely in a position to help the growth and production of biologics goods at each individual stage of the course of action whilst conference the evolving desires of biopharmaceutical businesses around the world. For additional information and facts, check out samsungbiologics.com.

Media Speak to
Claire Kim
Senior Director
Global Promoting Interaction Crew
Samsung Biologics
cair.kim@samsung.com

See first content material to obtain multimedia:https://www.prnewswire.com/news-releases/samsung-biologics-retains-11th-annual-normal-meeting-of-shareholders-301512301.html

Supply Samsung Biologics